We are an Intellectual Property (IP) Centric Company. IP is at the center of everything we do. We believe it is management's responsibility to invest tens of millions of dollars to develop product candidates that have a strong, proven  intellectual property base.

patented analogs of psychedelic compounds

We plan to develop patented analogs of psychedelic compounds. These analogs will be engineered to eliminate hallucinogenic properties – but retain key properties such as anti-inflammatory, neuroprotective and immunomodulatory activities.

Advances in psychiatric and psychedelic research have shown that to defeat serious mental illness, we need to change brain circuitry, brain structures, and patterns of gene expression. We need to modify the chemistry of the brain.


Pharmaceutical Patents


We seek "composition of matter" patents, also called product patents – the strongest possible type of patent which is not circumventable. This is what our substantial partners require.

We are not proponents of formulation, crystalline forms, and process patents. Our product candidates meet the stringent criteria for partnering with Big Pharma.

Intellectual Property - Patents

Our blended strategy of nutraceuticals and FDA-approved medicines is built on strong IP and provides a sustainable competitive advantage.

We are actively working on several valuable patent families. From our experience, strong IP strategies enhance and catalyze strategic deals with big pharma.


Global Psychedelic Drugs

Psychedelic drugs and psychedelic-inspired molecules are being evaluated in a range of serious neuropsychiatric and neurodegenerative disorders, including major depressive disorder and anxiety disorders such as PTSD, Alzheimer’s, and Parkinson’s disease.

The prevalence of these conditions is growing, as is the population of those who are resistant to currently available treatments. Novel drugs to address these unmet needs are sorely needed.